Statins in Lymphangioleiomyomatosis. Simvastatin and Atorvastatin Induce Differential Effects ontuberous sclerosis complex 2–Null Cell Growth and Signaling

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Nutrient Sensing, Metabolism, and Cell Growth Control

(2013) Hai-Xin Yuan et al.   MOLECULAR CELL

The Tangled Circuitry of Metabolism and Apoptosis

(2013) Joshua L. Andersen et al.   MOLECULAR CELL

HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway

(2013) X-F Qi et al.   Cell Death & Disease

Expanding the pleiotropic effects of statins: attenuation of air pollution-induced inflammatory response

(2012) D. R. Tasat et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Treatment Option(s) for Pulmonary Lymphangioleiomyomatosis: Progress and Current Challenges

(2012) Vera P. Krymskaya   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Lymphangioleiomyomatosis — a wolf in sheep’s clothing

(2012) Elizabeth P. Henske et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Statin Use and Reduced Cancer-Related Mortality

(2012) Sune F. Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update

(2012) John M. Kyriakis et al.   PHYSIOLOGICAL REVIEWS

Prevention of Alveolar Destruction and Airspace Enlargement in a Mouse Model of Pulmonary Lymphangioleiomyomatosis (LAM)

(2012) E. A. Goncharova et al.   Science Translational Medicine

PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects

(2011) Vera P. Krymskaya et al.   CELL CYCLE

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

(2011) D. M. Davies et al.   CLINICAL CANCER RESEARCH

mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells

(2011) E. A. Goncharova et al.   MOLECULAR AND CELLULAR BIOLOGY

Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size

(2011) Abdelhafid Saci et al.   MOLECULAR CELL

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

(2011) Sandra L. Dabora et al.   PLoS One

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

(2011) Christos G. Mihos et al.   RHEUMATOLOGY INTERNATIONAL

Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases

(2010) Lisa R. Young et al.   CHEST

Statin use and cancer risk: a comprehensive review

(2010) Denise M Boudreau et al.   Expert Opinion On Drug Safety

Statins in COPD

(2009) Surinder Janda et al.   CHEST

Statins in lymphangioleiomyomatosis: a word of caution

(2009) S. El-Chemaly et al.   EUROPEAN RESPIRATORY JOURNAL

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

(2009) Nancy Lee et al.   BMC Pharmacology & Toxicology

Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

(2008) Pertti J Neuvonen et al.   CLINICAL PHARMACOKINETICS

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE